A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
Clinical trial NCT07231068 · RECRUITING
Trial details
- NCT number
- NCT07231068
- Sponsor
- Henan Genuine Biotech Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-31
- Primary completion
- 2027-12-31
- Enrollment
- 153
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.